Helus Pharma Inc.
HELPHealthcare|Medical - Pharmaceuticals|CA
$8.96
+0.57 (+6.79%)
DCF Value
$3.20
About
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions. Its pipeline includes HLP003, in Phase 3 development for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder.
Stock Price
+51.6%(1Y)
1M
-16.4%
3M
-22.8%
6M
+68.7%
YTD
+9.5%
1Y
+51.6%
3Y
+51.6%
5Y
+51.6%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$555.4M
Employees100
CEOMichael I. Halstead
IPO DateSep 13, 2019
Beta0.54
52-Week Range$3.76 – $15.15
Avg Volume1,691,005
ExchangeNASDAQ
Websitehelus.com
Ownership
Float78.5%
Shares Outstanding62.0M
Recent Insider Trades
Durgam Suresh K.OTHER
Oct 16, 20260 shares
Lewis-Hall Freda COTHER
Oct 13, 20260 shares
Lewis-Hall Freda COTHER
Oct 13, 202625,000 shares @ $5.99
Lewis-Hall Freda COTHER
Oct 13, 202625,000 shares
Inamdar AmirOTHER
Oct 13, 20260 shares
Peers
BETR.CNBetterLife Pharma Inc.
$139.1MBNXT.CNBioNxt Solutions Inc.
$35.4MDRUG.CNBright Minds Biosciences Inc.
$256.5MLOBE.CNLobe Sciences Ltd.
$12.3MMDMA.CNPharmala Biotech Holdings Inc.
$16.4MMRVL.VMarvel Biosciences Corp.
$7.6MPHRM.CNPharmaTher Holdings Ltd.
$4.6MPHRX.CNPharmadrug Inc.
$671.1KRecent News
Cybin Inc. (NASDAQ:HELP) Stock Has Average Target Price of $47.33 According to Brokerages
Nov 7, 2026 · defenseworld.net
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
Nov 3, 2026 · globenewswire.com
Helus Pharma Announces Co-Founders' Transition from Executive Leadership as Company Advances Toward Next Stage of Development
Oct 27, 2026 · globenewswire.com
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Oct 21, 2026 · globenewswire.com
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
Oct 15, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:13 AM